language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
ARAYARAY

$0.4452

+0.01
arrow_drop_up1.53%
Current Market·update16 Apr 2026 20:00
Day's Range
0.4129-0.458
52-week Range
0.33-2.1

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2026-02-04
Next Earnings TimeAfter Market Close
Volume1.08M
Average Volume 30d1.29M

AI ARAY Summary

Powered by LiveAI
💰
-9.3
Valuation (P/E Ratio)
Negative P/E due to losses, consider forward P/E or other metrics.
📈
EPS Growth (YoY)
Year-over-year EPS data not directly available, current EPS is negative.
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Hold
65

Accuray Incorporated shows mixed signals, with some fundamental strengths in its niche but facing profitability challenges and a competitive landscape. Technicals are mixed, suggesting a 'Hold' recommendation for now.

Neutral

Thematic

60

Accuray operates in the medical device sector, focusing on radiation therapy and radiosurgery. Demand is driven by an aging global population and increased cancer diagnoses, but competition and technological disruption are key considerations.

Neutral

Fundamental

68

Accuray exhibits a mixed financial profile, with revenue growth over the past few years but persistent net losses and negative free cash flow in some periods. Its balance sheet shows manageable debt levels.

Bullish

Technical

65

Accuray's stock price has shown some positive momentum recently, trading above key moving averages. However, oscillators are mixed, suggesting potential for consolidation.

FactorScore
Healthcare Demand Growth75
Technological Advancement70
Competition50
Regulatory Environment65
Healthcare Spending Trends40
FactorScore
Valuation70
Profitability30
Growth45
Balance Sheet Health40
Cash Flow35
FactorScore
Trend Analysis50
Momentum60
Volume Confirmation70
Support & Resistance75

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (5)

Earnings Performance chevron_right

Positive EPS Surprise

Accuray Incorporated (ARAY) has demonstrated positive earnings per share (EPS) surprises in recent quarters, with the latest quarter (2025 Q1) reporting an EPS of $0.02 against an estimate of -$0.02, a surprise of 180.0%.

Financial Health & Liquidity chevron_right

Improving Cash Position

The company's cash and cash equivalents have shown an increasing trend, from $88.74 million in Q2 2022 to $68.57 million in Q2 2024, with positive operating cash flow in some recent periods indicating cash generation capability.

Show More 🔒
thumb_down

Bearish Points (7)

Growth and Profitability chevron_right

Negative Net Income and Margins

Accuray Incorporated has consistently reported negative net income and net margins across the observed annual and quarterly periods, indicating ongoing unprofitability. For example, in 2024 Q2, the net income was -$15.55 million with a net margin of -3.5%.

Debt Level and Coverage chevron_right

High Debt Relative to Cash

The company's debt level (e.g., $210.75 million in Q2 2024) is significantly higher than its cash and cash equivalents ($68.57 million in Q2 2024), and its free cash flow has been negative in Q2 2024 (-$15.51 million), raising concerns about debt servicing capability.

Show More 🔒

Calendar

August 2025

14

Next Earnings Date

EPS Est.
Revenue Est.

H: $0.03

A: $0.01

L: $0.00

H: 125.10M

A: 124.47M

L: 123.80M

Profile

Employees (FY)987
ISIN-
FIGI-

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Seasonals

2025
2024
2023
2022
2021

Price Target

5.17 USD

The 39 analysts offering 1 year price forecasts for ARAY have a max estimate of 7.00 and a min estimate of 4.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
99.2M (96.28%)
Closely held shares
3.83M (3.72%)
103M
Free Float shares
99.2M (96.28%)
Closely held shares
3.83M (3.72%)

Capital Structure

Market cap
140.1M
Debt
210.75M
Minority interest
0.00
Cash & equivalents
68.57M
Enterprise value
282.27M

Valuation - Summary

Market Cap
140M
Net income
-2.71M(-1.94%)
Revenue
331M(236.24%)
140M
Market Cap
140M
Net income
-2.71M(-1.94%)
Revenue
331M(236.24%)
Price to earning ratio (P/E)-51.60x
Price to sales ratio (P/S)0.40x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
446.55M
COGS
303.63M
Gross Profit
142.92M
OpEx
142.42M
Operating Income
504K
Other & Taxes
16.05M
Net Income
-15.54M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒